Literature DB >> 21670115

Attenuated but live: a pelvic abscess caused by bacille Calmette-Guerin.

Jerome A Leis1, Daniel R Ricciuto, Wayne L Gold.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21670115      PMCID： PMC3176844          DOI： 10.1503/cmaj.101853

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.

Authors:  Omar Y Gonzalez; Daniel M Musher; Indira Brar; Seth Furgeson; Maha R Boktour; Edward J Septimus; Richard J Hamill; Edward A Graviss
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

2.  The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer.

Authors:  M Al Khalifa; P Elfving; W Månsson; S Colleen; S Hellsten; M Duchek; G Nyberg; P Callaghan; C Rademark; R Eriksson; R Olsson; G Hagberg; C E Nelson
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

Review 3.  Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.

Authors:  S Prescott; A M Jackson; S J Hawkyard; A B Alexandroff; K James
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

4.  Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer.

Authors:  S J F Gerbrandy; L C Schreuders; M D de Smet
Journal:  Ocul Immunol Inflamm       Date:  2008 May-Jun       Impact factor: 3.070

Review 5.  Practical approaches to the prevention and treatment of adverse reactions to BCG.

Authors:  A P van der Meijden
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

6.  Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity.

Authors:  J I DeHaven; C Traynellis; D R Riggs; E Ting; D L Lamm
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 8.  Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.

Authors:  Mike D Shelley; Malcolm D Mason; Howard Kynaston
Journal:  Cancer Treat Rev       Date:  2010-01-15       Impact factor: 12.111

9.  Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy.

Authors:  Jared G Heiner; Martha K Terris
Journal:  Urol Oncol       Date:  2007-10-29       Impact factor: 3.498

10.  Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin (BCG).

Authors:  Eric Gomez; Tom Chiang; Ted Louie; Madhavi Ponnapalli; Robert Eng; David B Huang
Journal:  Int J Microbiol       Date:  2009-12-16
  10 in total
  1 in total

Review 1.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.